US20040266844A1 - Antimicrobial and radioprotective compounds - Google Patents

Antimicrobial and radioprotective compounds Download PDF

Info

Publication number
US20040266844A1
US20040266844A1 US10/481,667 US48166704A US2004266844A1 US 20040266844 A1 US20040266844 A1 US 20040266844A1 US 48166704 A US48166704 A US 48166704A US 2004266844 A1 US2004266844 A1 US 2004266844A1
Authority
US
United States
Prior art keywords
compound
formula
hydrogen
infection
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/481,667
Other languages
English (en)
Inventor
Peter Denisenko
Nikolay Sapronov
Alexander Tarasenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biodiem Ltd
Original Assignee
Biodiem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodiem Ltd filed Critical Biodiem Ltd
Assigned to BIODIEM LTD. reassignment BIODIEM LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DENISENKO, PETER PROKOFIEVICH, SAPRONOV, KIKOLAY SERGEEVICH, TARASENKO, ALEXANDER ALEXANDROVICH
Publication of US20040266844A1 publication Critical patent/US20040266844A1/en
Priority to US11/923,404 priority Critical patent/US7825145B2/en
Priority to US12/776,896 priority patent/US8158664B2/en
Priority to US13/425,054 priority patent/US8569363B2/en
Assigned to BIODIEM LTD reassignment BIODIEM LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DENISENKO, PETER PROKOFIEVICH, SAPRONOV, NIKOLAY SERGEEVICH, TARASENKO, ALEXANDER ALEXANDROVICH
Priority to US14/026,641 priority patent/US9045452B2/en
Priority to US14/728,854 priority patent/US20150258059A1/en
Assigned to BIODIEM LTD reassignment BIODIEM LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DENISENKO, PETER PROKOFIEVICH, SAPRONOV, NIKOLAY SERGEEVICH, TARASENKO, ALEXANDER ALEXANDROVICH
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to compounds which have antimicrobial and radioprotective activity.
  • the invention relates to substituted nitrostyrene compounds which have activity against a wide spectrum of organisms including bacteria, fungi and protozoa.
  • the compounds of the invention also have the ability to provide protection from radiation damage.
  • Bacterial, fungal and protozoal pathogens are responsible for a very wide variety of infections, ranging from minor respiratory ailments to fulminant systemic infections and chronic illnesses. Food poisoning caused by organisms such as Salmonella or Campylobacter is common, and is often associated with endemic infection in livestock or poultry raised using intensive animal husbandry techniques.
  • R 1 ′ is H or CH 3 ;
  • R 2 ′ and R 3 ′ are the same or different and are selected from H, OCH 3 , OH, NO 2 and (CH 3 ) 2 N.
  • the invention provides a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula I:
  • X and Y are either the same or different and selected from a heteroatom
  • [0016] is a double or single bond depending on the heteroatoms X and Y;
  • R 1 to R 5 are either the same or different and selected from hydrogen or a non-deleterious substituent
  • R 6 and R 7 are either the same or different and selected from hydrogen and a non-deleterious substituent or one of R 6 and R 7 are absent when there is a double bond present,
  • the invention also provides use of the compound of formula I in the manufacture of a medicament for the treatment and/or prophylaxis of a microbial infection.
  • the invention further provides use of the compound of formula I for the treatment and/or prophylaxis of a microbial infection.
  • the invention still further provides a method for protecting a subject from radiation damage which comprises administering an effective amount of the compound of formula I to a subject in need thereof.
  • the invention provides a method of cancer radiotherapy which comprises administering to a subject in need of such therapy an effective amount of the compound of formula I and subjecting the locus of a tumour in the subject to a radiation source.
  • the invention provides use of the compound of formula I as an antimicrobial or radioprotective agent.
  • X and Y are either the same or different and selected from O and N, more preferably both X and Y are oxygen.
  • R 1 and R 2 are either the same or different and selected from hydrogen, hydroxy, halogen or optionally substituted C 1-6 alkyl.
  • R 3 to R 5 are preferably either the same or different and selected from hydrogen, hydroxy, halogen, nitro, C 1-6 alkoxy or optionally substituted C 1-6 alkyl.
  • halogen is chlorine or bromine.
  • X and Y are O, R 1 is methyl and R 2 and R 3 are hydrogen (3,4-methylenedioxy- ⁇ -methyl- ⁇ -nitrostyrene)
  • R 8 is C 1-12 alkyl or phenyl optionally substituted by one or more halogen
  • R 2 , R 3 , R 5 , R 6 and R 7 are hydrogen, R 4 is OCH 3 and X and Y are O, then R 1 is not H, CH 3 or CH 2 CH 3 ;
  • the invention also provides a process for the preparation of the compound of formula Ia defined above which comprises condensing a compound of formula II:
  • the invention further provides a process for the preparation of the compound of formula Ia defined above which comprises reacting a compound of formula IV:
  • the processes are preferably performed in the presence of a catalyst, such as, an amine or an alkali metal hydroxide, for example, NaOH or KOH.
  • a catalyst such as, an amine or an alkali metal hydroxide, for example, NaOH or KOH.
  • the invention provides a pharmaceutical or veterinary composition
  • a pharmaceutical or veterinary composition comprising the compound of formula Ia defined above together with a pharmaceutically or veterinarily acceptable carrier.
  • the pharmaceutical or veterinary composition is a topical, oral or parenteral composition.
  • the pharmaceutically or veterinarily acceptable carrier is preferably an organic solvent such as acetone, benzene, acetonitrile, DMSO or an alcohol, for example, methanol or ethanol. While the compounds of the present invention show a poor solubility in water, when water is combined with an organic solvent a stable mixture is formed.
  • heteroatom denotes O, N or S.
  • non-deleterious substituent is used herein in its broadest sense and refers to a substituent which does not have a deleterious effect on the antimicrobial or radioprotective properties of the compound.
  • examples include alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, diarylamino, benzylamino, dibenzylamino, acyl
  • Particularly suitable non-deleterious substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, nitroalkyl, nitroalkenyl and nitroalkynyl.
  • non-deleterious substituents are C 1-6 alkyl, halo, hydroxy, C 1-6 alkoxy and nitro.
  • halogen refers to fluorine, chlorine, bromine and iodine, preferably chlorine and bromine.
  • alkoxy is used herein in its broadest sense and refers to straight chain, branched chain or cyclic oxy-containing radicals each having alkyl portions, preferably C 1-6 alkyl, more preferably C 1-4 alkyl. Examples of such alkoxy groups are methoxy, ethoxy, propoxy, butoxy and t-butoxy.
  • C 1-4 alkyl or C 1-6 alkyl used either alone or in compound words such as “optionally substituted C 1-4 or C 1-6 alkyl” refer to straight chain, branched chain or cyclic hydrocarbon groups having from 1 to 6 carbon atoms. Illustrative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • salts of the compound of formula I or Ia are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts.
  • Examples of pharmaceutically acceptable salts include salts of pharmaceutically acceptable cations such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium; acid addition salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, trihalomethanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, as
  • solvates may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
  • pharmaceutically acceptable derivative any pharmaceutically acceptable salt, hydrate or any other compound which, upon administration to the subject, is capable of providing (directly or indirectly) a compound of formula I or Ia or an antimicrobial or radioprotective active metabolite or residue thereof.
  • pro-drug is used herein in its broadest sense to include those compounds which are converted in vivo to compounds of formula I or Ia.
  • tautomern is used herein in its broadest sense to include compounds of formula I or Ia which are capable of existing in a state of equilibrium between two isomeric forms. Such compounds may differ in the bond connecting two atoms or groups and the position of these atoms or groups in the compound.
  • microbial infection is used herein in its broadest sense and refers to any infection caused by a microorganism and includes bacterial infections, fungal infections, yeast infections and protozoal infections.
  • microorganism includes any microscopic organism or taxonomically related macroscopic organism within the categories algae, bacteria, fungi, yeast and protozoa or the like.
  • Bacterial infections include, but are not limited to, infections caused by Bacillus cereus, Bacillus anthracis, Clostridium botulinum, Clostridium difficile, Clostridium tetani, Clostridium perfringens, Corynebacteria diphtheriae, Enterococcus ( Streptococcus D ), Listeria monocytogenes, Pneumoccoccal infections ( Streptococcus pneumoniae ), Staphylococcal infections and Streptococcal infections ; Gram Negative bacteria including Bacteroides, Bordetella pertussis, Brucella, Campylobacter infections, enterohaemorrhagic Escherichia coli (EHEC/ E.
  • EHEC/ E enterohaemorrhagic Escherichia coli
  • enteroinvasive Escherichia coli EIEC
  • enterotoxigenic Escherichia coli ETEC
  • Haemophilus influenzae Helicobacter pylori
  • Klebsiella pneumoniae Legionella spp.
  • Moraxella catarrhalis Neisseria gonnorrhoeae
  • Neisseria meningitidis Proteus spp.
  • Pseudomonas aeruginosa Salmonella spp., Shigella spp., Vibrio cholera and Yersinia
  • acid fast bacteria including Mycobacterium tuberculosis, Mycobacterium avium - intracellulare, Myobacterium johnei, Mycobacterium leprae , atypical bacteria, Chlamydia, Mycoplasma, Rickettsia, Spirochetes, Treponema pallidum, Borrelia recurrentis, Borreli
  • Fungal infections include, but are not limited to, infections caused by Alternaria alternata, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, Aspergillus versicolor, Blastomyces dermatiditis, Candida albicans, Candida dubliensis, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida glabrata, Coccidioides immitis, Cryptococcus neoformans, Epidermophyton floccosum, Histoplasma capsulatum, Malassezia furfur, Microsporum canis, Mucor spp., Paracoccidioides brasiliensis, Penicillium marneffel, Pityrosporum ovale, Pneumocystis carinii, Sporothrix schenkii, Trichophyton rubrum, Trichophyton interdigitale, Trichosporon beigelii
  • Yeast infections include, but are not limited to, infections caused by Brettanomyces clausenii, Brettanomyces custerii, Brettanomyces anomalous, Brettanomyces naardenensis, Candida himilis, Candida intermedia, Candida saki, Candida solani, Candida tropicalis, Candida versatilis, Candida bechii, Candida famata, Candida lipolytica, Candida stellata, Candida vini, Debaromyces hansenii, Dekkera intermedia, Dekkera bruxellensis, Geotrichium sandidum, Hansenula fabiani, Hanseniaspora uvarum, Hansenula anomala, Hanseniaspora guillermondii Hanseniaspora vinae, Kluyveromyces lactis, Kloekera apiculata, Kluveromyces marxianus, Kluyveromyces fragilis, Metschikowia pulcherrima, Pichia guilliermod
  • Protozoal infections include, but are not limited to, infections caused by Leishmania, Toxoplasma, Plasmodia, Theileria, Anaplasma, Giardia, Trichomonas, Trypanosoma, Coccidia, and Babesia. Specific examples include Trypanosoma cruzi, Eimeria tenella, Plasmodium falciparum, Plasmodium vivax or Plasmodium ovale.
  • microbial infections include bacterial or fungal wound infections, mucosal infections, enteric infections, septic conditions, pneumonia, trachoma, ornithosis, trichomoniasis, fungal infections and salmonellosis, especially in veterinary practice.
  • the compounds of the invention may also be used for the treatment of resistant microbial species or in various fields where antiseptic treatment or disinfection of materials is required, for example, surface disinfection.
  • subject refers to any animal having a disease or condition which requires treatment with a pharmaceutically-active agent.
  • the subject may be a mammal, preferably a human, or may be a domestic or companion animal. While it is particularly contemplated that the compounds of the invention are suitable for use in medical treatment of humans, it is also applicable to veterinary treatment, including treatment of companion animals such as dogs and cats, and domestic animals such as horses, ponies, donkeys, mules, llama, alpaca, pigs, cattle and sheep, or zoo animals such as primates, felids, canids, bovids, and ungulates.
  • Suitable mammals include members of the orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and Artiodactyla. Members of the orders Perissodactyla and Artiodactyla are particularly preferred because of their similar biology and economic importance.
  • Artiodactyla comprises approximately 150 living species distributed through nine families: pigs ( Suidae ), peccaries ( Tayassuidae ), hippopotamuses ( Hippopotamidae ), camels ( Camelidae ), chevrotains ( Tragulidae ), giraffes and okapi ( Giraffidae ), deer ( Cervidae ), pronghorn ( Antilocapridae ), and cattle, sheep, goats and antelope ( Bovidae ). Many of these animals are used as feed animals in various countries. More importantly, many of the economically important animals such as goats, sheep, cattle and pigs have very similar biology and share high degrees of genomic homology.
  • the order Perissodactyla comprises horses and donkeys, which are both economically important and closely related. Indeed, it is well known that horses and donkeys interbreed.
  • the term “effective amount” is meant an amount of a compound of the present invention effective to yield a desired antimicrobial or radioprotective activity.
  • radiation damage is used herein in its broadest sense and refers to damage resulting from exposure to a radiation source, such as, ionising radiation.
  • ionising radiation refers to photons having enough energy to ionise a bond, such as, ⁇ , ⁇ and ⁇ rays from radioactive nuclei and x-rays.
  • cancer radiotherapy is used herein in its broadest sense and include radiotherapy involving tumours which may be either benign or malignant.
  • the primary application of the radioprotector of the present invention is in cancer radiotherapy.
  • Many of the normal tissues which are a problem in radiotherapy such as the skin, oral mucosa, oesophageal mucosa, rectal mucosa, vaginal mucosa and bladder epithelium can be protected by the radioprotectors of the present invention.
  • the radioprotectors of the present invention could be used prophylactly in high risk radiation situations.
  • the compounds of the present invention may additionally be combined with other medicaments to provide an operative combination. It is intended to include any chemically compatible combination of pharmaceutically-active agents, as long as the combination does not eliminate the activity of the compound of formula I or Ia. It will be appreciated that the compound of the invention and the other medicament may be administered separately, sequentially or simultaneously.
  • medicaments which may be used when treating microbial infections include other anti-infective agents such as antibiotics.
  • the other medicaments may include chemotherapeutic agents, for example, radiomimetic agents which are cytotoxic agents that damage DNA in such a way that the lesions produced in DNA are similar to those resulting from ionising radiation.
  • chemotherapeutic agents for example, radiomimetic agents which are cytotoxic agents that damage DNA in such a way that the lesions produced in DNA are similar to those resulting from ionising radiation.
  • radiomimetic agents which cause DNA strand breaks include bleomycin, doxorubicin, adriamycin, 5FU, neocarcinostatin, alkylating agents and other agents that produce DNA adducts. It is anticipated that the radioprotectors of the present invention will protect DNA from damage by some of these agents, in the same way as they protect against the effects of ionising radiation. In clinical applications, it is unlikely that the radioprotector would be administered systemically together with the chemotherapeutic agent, since this could compromise the action of this agent on the tumour. However, there are circumstances where topical application to problem tissues could be advantageous.
  • oral mucositis is problem side-effect for cytotoxic agents, such as, doxorubicin and administration of the present radioprotector as a mouth-wash before administration of the chemotherapeutic agent could ameliorate this side-effect without compromising the action of this agent on a tumour not located in the oral cavity.
  • cytotoxic agents such as, doxorubicin
  • administration of the present radioprotector as a mouth-wash before administration of the chemotherapeutic agent could ameliorate this side-effect without compromising the action of this agent on a tumour not located in the oral cavity.
  • the gastrointestinal tract could be protected by oral administration, the lungs by aerosol inhalation or the bladder by intravesical delivery, for example, via a catheter of the radioprotector.
  • a preferred method in accordance with the present invention utilises the compound of formula I or Ia in conjunction with another medicament, such as, a radiomimetic agent.
  • the compounds of the invention may be conjugated to agents, for example, via the interactive group, which will specifically deliver them to a desired tumour site.
  • Suitable agents may include antibodies or proteins, growth factors, for example, haemopoietic growth factor which will enable preferential radioprotection of haemopoietic stem cells to occur in the context of total body irradiation and bone marrow transplantation.
  • Bone marrow transplantation generally involves obtaining and storing bone marrow samples from a subject in anticipation of a deterioration of their condition. A rather drastic form of chemotherapy (i.e. a high dose) is then administered. This chemotherapy is such that it would normally be lethal due to the destruction of normal stem cells, but the subject is rescued by the administration of their own haemopoietic stem cells. The problem with this procedure is that the initial sample of stem cells is likely to be contaminated with tumour cells and various procedures are use therefore to purge the bone marrow preparations of the tumour cells.
  • Radioprotectors conjugated to a haemopoietic growth factor could be used in this context by being added to a suspension of bone marrow cells. The suspension could then be irradiated in the expectation that the normal bone marrow cells, but not the tumour cells, would be preferentially protected from the cell-killing effects of the radiation.
  • a “pharmaceutical carrier” is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the compound of formula I or Ia to the subject.
  • the carrier may be liquid or solid and is selected with the planned manner of administration in mind.
  • Each carrier must be pharmaceutically “acceptable” in the sense of being compatible with other ingredients of the composition and non injurious to the subject.
  • the compound of formula I or Ia may be administered orally, topically, or parenterally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles.
  • parenteral as used herein includes subcutaneous injections, aerosol for administration to lungs or nasal cavity, intravenous, intramuscular, intrathecal, intracranial, injection or infusion techniques.
  • the present invention also provides suitable topical, oral and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
  • the compounds of the present invention may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs.
  • the composition for oral use may contain one or more agents selected from the group of sweetening agents, flavouring agents, colouring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations.
  • Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharin.
  • Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar.
  • Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring.
  • Suitable preservatives include sodium benzoate, vitamin E, alphatocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite.
  • Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc.
  • Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
  • the tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents such as corn starch or alginic acid
  • binding agents such as starch, gelatin or acacia
  • lubricating agents such as magnesium stearate, stearic acid or talc.
  • These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as gly
  • the compound of formula I or Ia as well as the pharmaceutically-active agent useful in the method of the invention can be administered, for in vivo application, parenterally by injection or by gradual perfusion over time independently or together. Administration may be intravenously, intraarterial, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally or infusion by, for example, osmotic pump. For in vitro studies the agents may be added or dissolved in an appropriate biologically acceptable solvent or buffer and added to a cell or tissue.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, growth factors and inert gases and the like.
  • the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure of a disease.
  • Treating covers any treatment of, or prevention of disease in a vertebrate, a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject that may be predisposed to the disease, but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or (c) relieving or ameliorating the effects of the disease, i.e., cause regression of the effects of the disease.
  • the invention includes various pharmaceutical compositions useful for ameliorating disease.
  • the pharmaceutical compositions according to one embodiment of the invention are prepared by bringing a compound of formula I or Ia, analogues, derivatives or salts thereof, or combinations of compound of formula I or Ia and one or more pharmaceutically-active agents into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries.
  • carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols.
  • Intravenous vehicles include fluid and nutrient replenishers.
  • Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases.
  • Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 20th ed. Williams & Williams (2000), the British National Formulary, 43 rd edition (British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000), the contents of which are hereby incorporated by reference.
  • the pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed., 1985).
  • the pharmaceutical compositions are preferably prepared and administered in dose units.
  • Solid dose units may be tablets, capsules and suppositories.
  • different daily doses can be used for treatment of a subject. Under certain circumstances, however, higher or lower daily doses may be appropriate.
  • the administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.
  • compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject.
  • dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of the microbial infections.
  • animal models may be used to determine effective dosages for treatment of the microbial infections.
  • Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension.
  • excipients may be (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono-or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compound of formula I or Ia may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
  • the compound of formula I or Ia may also be presented for use in the form of veterinary compositions, which may be prepared, for example, by methods that are conventional in the art.
  • veterinary compositions include those adapted for:
  • drenches e.g. aqueous or non-aqueous solutions or suspensions
  • tablets or boluses powders, granules or pellets for admixture with feed stuffs; pastes for application to the tongue;
  • parenteral administration for example by subcutaneous, intramuscular or intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced in the udder via the teat;
  • topical applications e.g. as a cream, ointment or spray applied to the skin; or
  • Dosage levels of the compound of formula I or Ia of the present invention may be of the order of up to about 1 g per kilogram body weight.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for oral administration to humans may contain up to about 1 g of an active compound with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 5 mg to about 500 mg of active ingredient.
  • the compounds of the invention are administered in a divided dose schedule, such that there are at least two administrations in total in the schedule. Administrations are given preferably at least every two hours for up to four hours or longer; for example the compound may be administered every hour or every half hour.
  • the divided-dose regimen comprises a second administration of the compound of the invention after an interval from the first administration sufficiently long that the level of active compound in the blood has decreased to approximately from 5-30% of the maximum plasma level reached after the first administration, so as to maintain an effective content of active agent in the blood.
  • one or more subsequent administrations may be given at a corresponding interval from each preceding administration, preferably when the plasma level has decreased to approximately from 10-50% of the immediately-preceding maximum.
  • FIG. 1 is a graph of Log. No. survivors vs time (hours) for Candida albicans in Example 9;
  • Benzdioxols are described in the literature (Perekalkin, 1982a).
  • the synthesis of benzoimidazole and benzoxazole may also be carried out using standard condensation methods 1 and 2 (Perekalkin, 1966, 1982b) as shown below.
  • the product was purified by dissolving in a minimal quantity of boiling alcohol. It was then treated with activated carbon, filtered hot and while the cooling was in progress, fine yellow needles crystallised. The yield was about 80-85%, the compound being chromatographically homogeneous.
  • the compounds were soluble in organic solvents such as ethanol, acetone, benzene, methanol, acetonitrile, chloroform and DMSO, but showed very poor solubility in water (0.1%). When an alcoholic solution was added to water, a stable colloidal mixture was formed.
  • the mixture was thoroughly shaken, covered with a layer of ether and a mixture of 6.7 cm 3 of 33% solution of caustic potassium (1.03 mole) and 50 cm 3 of water was added in small portions.
  • the mixture was shaken after each addition and once the entire amount of alkali was added, the shaking was continued until the entire salt of pyridine and nitroform, which is present as a dark red oil, disappeared.
  • the water layer was then separated and again extracted with ether. Combined ether extracts were first rinsed with water and then with water acidified with sulphuric acid and finally once again with pure water.
  • Nitrogroup at low wave number e.g. 747, 673 and ⁇ -nitrostyrene has 1520.
  • Hydrogen NMR (200 MHz) shows: Aromatic ring with 3 remaining Hs, 3 Hs as part of a CH 3 , another attached to the side chain and 2 Hs as part of another ring.
  • Recrystallised material has peaks (broad) at 250-270 mm and 360-370 mm with high absorbance below 210 mm.
  • the agar diffusion assay was performed as follows.
  • Meat peptone agar was prepared and impregnated with the test compounds at concentrations from 0.01 to 2.0%. The medium was poured into Petri dishes and allowed to set. Agar plugs of 10 mm diameter were cut out and placed on the surface of Petri dishes containing the same medium immediately after they were inoculated with the microorganisms to be investigated (at least 6 plugs per culture). After one day of incubation at 37° C., the diameter of the zone of retardation of growth of the culture around the plugs was measured. The results were evaluated in accordance with official standards of testing sensitivity to antibiotics; a diameter ⁇ 20 mm corresponded to a stable culture, 21-28 mm to moderate stability and >29 mm to sensitivity.
  • Table 1 shows the results of experiments with Compound (1) at a concentration of 1.0%, at which it suppressed the propagation of 5 ⁇ 10 5 -5 ⁇ 10 7 organisms/mL, and comparative results of sensitivity experiments using the following 15 antibiotics:
  • Table 2 shows the results of experiments on sensitivity of some microorganisms to Compound (1) using the agar diffusion method described above.
  • TABLE 2 Diameter of zone of Growth inhibition (mm) Concentration in disc of Compound (1) (%)
  • Microorganism 2.0 1.0 0.1 ⁇ -haemolytic 35# 34# 32# streptococcus B-672 ⁇ -haemolytic 31# 32# 31# streptococcus B-624 Staphylococci aureus 39# 37# 35# B-685 Staphylococci 38# 34# 32# epidermidis B-513 Shigella flexneri M- 36# 33# 31# 2A6907 Shigella sonnei B- 39# 35# 30# 720 Salmonella 32# 30# 24# typhimurium M-727 Salmonella paratyphi 36# 30# 28# M-16469 Acinetobacter B-681 38# 35# 32# Alkaligenes sp. 40# 38# 36# B-689 Enterobacter 33#
  • Table 3 shows the results of experiments of sensitivity of pathogenic fungi to compound (1). TABLE 3 Number of microbes in the presence of Compound (1) at Dosage of concentration (%) Fungi Inoculation Result 2.0 0.5 0.1 Candida 5 ⁇ 10 4 Growth 0 0 0 albicans B-45 Retardation 5 ⁇ 10 4 5 ⁇ 10 6 5 ⁇ 10 6 Candida 5 ⁇ 10 4 Growth 0 0 0 albicans M-3 Retardation 5 ⁇ 10 6 5 ⁇ 10 6 5 ⁇ 10 6 Trichophyton 10 2 Growth 0 0 0 Retardation 10 7 10 7 10 7 Geotrichum 10 5 Growth 0 0 0 M-158 Retardation 10 5 10 5 10 4 Torula 10 5 Growth 0 0 0 histolytica Retardation 10 5 10 5 10 5 ( Cryptococcus )
  • Staphylococcus aureus strain 674 isolated from a patient, sensitive to gentamycin, oxacillin, tetracycline,erythromycin and cephalothin, slightly sensitive to streptomycin.
  • Klebsiella pneumoniae strain 312 isolated from a patient, sensitive to gentamycin and polymyxin.
  • Salmonella typhimurium museum strain 727 sensitive to ampicillin, gentamycin, carbenicillin, canamicillin, polymyxin, and cephalothin.
  • Acinetobacter strain 681 isolated from a patient, slightly sensitive to polymyxin.
  • Table 5 below shows the results of the agar diffusion experiments. TABLE 5 Results of growth retardation by the compounds in the diffusions in the agar experiment Size of zone of retardation Test culture of the growth by Compound (1) Staphylococcus aureus 6.5 Enterococcus fecalis 6 Klebsiella pneumonia 5 Salmonella typhimurium 7 Acinetobacteria 6.5 Pseudonomas 0 Average zone of retardation 5.17
  • Compound (1) inhibits the growth of ampicillin-resistant Staphylococcus and the growth of Enterococcus which is sensitive to this antibiotic. Similar differences can be observed with other pathogens and other preparations.
  • Test culture was Mycobact tub. H.37RV sensitive to anti TB medication.
  • Results were calculated for 10-14 days incubation at 37° C. MIC (totally inhibiting M. tuberculosis)
  • Trichomonas vaginalis isolated from patients was used.
  • the trichomonads were cultured at pH 5.8-6.5 and 37° C. in medium 199 containing 5.0% native foetal calf serum, carbohydrates, and antibiotics to suppress the accompanying flora.
  • Vaseline was applied to the surface of the medium in the culture tube.
  • the experimental specimens contained the test compounds at a concentration of 0.3%.
  • Compounds (1) and (2) were administered intraperitoneally, intramuscularly and orally at a dose of ⁇ 20% LD 50 /0.2 at different periods from the day of infection, ie 2 and 1 days before the infection (schedules 2, 1), on the day of infection (schedule 0) and 1, 2, 3 etc. days after the infection (schedules +1, +2, +3, etc).
  • AI [( B ⁇ A ): B ] ⁇ 100
  • AI activity index of the preparation (%)
  • B cumulative mortality in the control group.
  • Table 8 shows the results of the experiments on radiation performance of the compounds investigated. TABLE 8 Cumulative mortality in groups % Dosage R (hR*) control prophylactic 2 2.9 0 4 3.6 0 6 13.1 3.8 8 21.1 9.5 10 43.8 13.3 15 66.7 45.5 20 94.1 83.3 FCD 1.39 + 1.48 LD 50 10.73 hR 15.88 hR
  • mice when administered intragastrically was 1500 mg/kg body weight; when administered intraperitonally the average lethal dose was 575 mg/kg body weight.
  • the compounds of the invention have low toxicity.
  • Compound (1) is relatively insoluble in water but is soluble in 10% DMSO at 1 mg/mL (0.1%), 10% ethanol at 2 mg/ml and 10% acetone at 2 mg/mL.
  • the highest concentration testable is either 512 ⁇ g/mL at 5% solvent or 256 ⁇ g/mL at 2.5% solvent. It does not require specific chemical neutralization, dilution being sufficient to neutralize residual activity in microbicidal testing.
  • DMSO was selected as the solvent for testing because it has the lowest toxicity against test strains.
  • Compound (1) was at least 8 times more active against E. coli when formulated in ethanol, giving an MIC of 128 ⁇ g/mL (0.06% ETOH) compared to >512 ⁇ g/mL (2.5% DMSO). Ethanol is toxic to E. coli at concentrations >2.5%.
  • MIC Minimum inhibitory concentration
  • MMC minimum bactericidal concentration
  • Compound (1) is a relatively broad spectrum antibacterial agent with bactericidal activity within an acceptable concentration range in vitro for a representative selection of Gram positive and Gram negative bacteria.
  • Compound (1) is broadly effective against aerobic Gram positive and Gram negative cocci and aerobic Gram positive rods of clinical significance.
  • Clinical isolates multiple antibiotic resistance of S. aureus and E. faecalis were as susceptible as the standard strains. Although not active at the low concentrations cf current treatment drugs, there may be a potential use for Compound (1) as a treatment for multiply resistant staphylococci and enterococci not responding to the current drugs of choice.
  • Compound (1) is active against clinically significant anaerobes, Clostridium perfringens, Clostridium difficile and Bacteroides fragilis.
  • C. difficile causes enterocolitis in hospitalized patients and is currently treated with vancomycin as the drug of choice. Induction of resistance is a potential problem with vancomycin.
  • vancomycin There could be a market for an oral drug for C. difficile enterocolitis as an alternative to vancomycin.
  • Anaerobic infections are generally mixed infections of one or more anaerobes with facultative bacteria, usually enteric Gram negative rods.
  • the most common anaerobic pathogens are Clostridium difficile and Bacteroides fragilis .
  • Current treatment with metronidazole in combination with other antibacterial drugs is generally efficacious. Given Compound (1)'s broad spectrum against both aerobic and anaerobic bacteria this could possibly treat these infections.
  • Campylobacter jejuni is the greatest cause of enteric infections worldwide and is often treated because of its severity in some patients and the tendency for infection to predispose to development of Guillain-Barre syndrome, a serious CNS disease.
  • enteric Gram negative bacteria could be a function of solubility and ability of Compound (1) to penetrate cells.
  • the successful treatment of recalcitrant enteric infections and the successful treatment of Salmonella infection in animals has been shown.
  • Compound (1) is active against Neisseria gonorrhoeae .
  • Vulvo-vaginitis is caused by Candida albicans, N. gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis (singly, not as co-infections).
  • Compound (1) is active against two of these agents.
  • faecalis - clinical isolate 1 32 32 1 1 E. faecalis - clinical isolate 2 32 32 Streptococcus pyogenes 16,8 16,8 Streptococcus pneumoniae ATCC49619 16 32 Bacillus subtilis RMIT 16 16 Corynebacterium xerosis RMIT 32,16 32,16 Clostridium perfringens (48 h) 16 32 Clostridium difficile 4 Gram negative Moraxella catarrhalis RMIT 32 32 Neisseria gonorrhoeae WHO Strain VII 2 2 Haemophilus influenzae 0.125 0.125 0.006 0.006 Bacteroides fragilis (48 h) 16 32 Campylobacter spp.
  • Compound (1) is fungicidal at relatively low concentrations against a broad range of clinically significant yeasts and filamentous fungi (Table 10).
  • Compound (1) shows good activity against 3 major causes of skin, hair and nail infections in humans and animals.
  • Superficial fungal infections are the most common fungal infections worldwide. Treatment is prolonged, over months (and years for nail infections). Superficial treatments with antifungal lotions and creams is only partially effective. Current treatments, although generally low cost, have poor efficacy and frequent relapse rates.
  • Oral systemic agents terbinafine and itraconazole are preferred for superficial infections in compromised patients and nail infections.
  • Compound (1) has a broad spectrum, is fungicidal and has failed to induce resistance in C. albicans and A. fumigatus (see below). TABLE 10 MIC/MFC ( ⁇ g/mL) for Compound (1) and miconazole against clinically significant fungi Compound (1)
  • Compound (1) 512 ⁇ g/mL did not kill B. subtilis endospores in 24 hours.
  • Compound (1) 512 ⁇ g/mL killed A. fumigatus exospores at 24 hours but not 6 hours.
  • Bacterial and fungal strains were exposed to Compound (1) in sub-inhibitory concentrations continuously for 12 weeks and monitored for a rise in MIC indicating development of resistance mechanisms.
  • a heavy and variable inoculum is used for weekly subculture so inhibitory concentrations each week vary.
  • the standardized MIC is measured at the beginning and end of exposure.
  • a greater than 4-fold variation of standardized MIC is indicative of increased resistance, or a rising trend in weekly MIC.
  • the genera selected are known to develop resistance readily to many antibiotics and to be a major clinical problem.
  • Compound (1) appeared to be relatively unaffected by the presence of 10% plasma and to be more active in the presence of 5% whole blood.
  • the slightly improved inhibitory activity of drugs in the presence of blood sometimes occurs with antibacterial agents and is probably due to natural antibacterial factors present in blood.
  • Further increasing the concentration of plasma and blood reduced the bactericidal activity of Compound (1) against S. aureus as shown in Table 13.
  • Ciprofloxacin showed respectively a 4-fold and 2-fold decrease in activity against S aureus in the presence of 10% plasma and whole blood.
  • TABLE 12 Activity of Compound (1) in the presence of human whole blood and plasma ⁇ g/mL — 10% plasma 5% blood MIC MIC MMC MIC MMC S. aureus 16 16 256 16 256 B. subtilis 16 8 8 8 16 A. calcoaceticus 128 128 128 64 256 M. catarrhalis 32 8 8 4 8
  • Compound (1) The MIC of Compound (1) was determined in increasing concentrations of plasma. Compound (1) has been shown to bind to human serum albumin and to agarose. Serum binding is significant in drug distribution and bioavailability.
  • Test strains were inoculated into Compound (1) solutions in water and sampled immediately and at 1, 2, 4, 6 and 9 hours. Survivors were estimated by viable counts on MHA (35° C., 48).
  • Compound (1) showed rapid kill only against Candida albicans , with greater than a 99.999% reduction within 2 hours at 512 ⁇ g/mL and within 4 hours at 256 ⁇ g/mL as shown in FIG. 1.
  • Rate of kill was much slower against bacteria.
  • the kill rate at 512 ⁇ g/mL was 99.99% within 2 hours for B. subtilis and 9.99% within 9 hours for S. aureus.
  • Ciprofloxacin was not tested. TABLE 14 Log reduction factors for Compound (1) over 6 or 9 hours Log reduction in viable count at time (h) Compound (1) ⁇ g/mL 512 256 128 Staphylococcus aureus 4 in 9 h 0.5 in 6 h Enterococcus faecalis 0.6 at 9 h Bacillus subtilis 4 in 2 h 3.8 in 2 h Klebsiella oxytoca 0 0 Proteus vulgaris 1 in 6 h 0.5 in 6 h Acinetobacter calcoaceticus 1 in 6 h 1 in 6 h Candida albicans 5.5 at 2 h 6 in 4 h 2 in 6 h
  • the aim of this example was to establish absorption and blood levels of Compound (1) in the rat after a single dose oral administration.
  • Sprague-Dawley rats (6 w/o, delivered 30 Jan, 2001) were acclimatised for 6 days in the Animal Facility under standardized environmental conditions (22° C. ⁇ 3° C., rel hum 30-70%, artificial light, 12 h light/12 h dark). Rats were fed a conventional laboratory diet with food and water ad lib and caged 5 rats per cage.
  • Compound (1) was prepared as an aqueous suspension in sterile LPW. At higher concentrations the suspension was sonicated to reduce particle size sufficiently to pass through the gavage needle.
  • Compound (1) was tested at 1250, 1000, 500 and 100 mg/kg.
  • Rats were randomly assigned to treatment groups, identified by numbering on tails. Doses were tested sequentially from the lowest dose. Group A 100 mg/kg 5/2/01 B 500 8/2/01 (not fasted) C 500 12/2/01 (fasted) D 1000 14/2/01 E 1250 21/2/01
  • Compound (1) suspensions and the water control were administered at approx 100 mL/kgbw, in a single.
  • One control and five treatment rats were weighed immediately before each dose administration, the dose volume calculated and the dose delivered by gavage (22 gauge stainless steel, smooth-balled end attached to a syringe).
  • Compound (1) was extracted ( ⁇ 2) from serum by toluene and absorbance measured at 370 nm (Hitachi U2000). A spiked control using 100 ⁇ g/mL Compound (1) in 50% methanol/water (V/V) and untreated controls were also assayed.
  • NCCLS-USA Broth Macrodilution method (RPMI medium) —draft. Inoculum 1-4 ⁇ 10 5 cfu. Miconazole control. This test was used for initial activity spectrum evaluations.
  • Results are of 2 or 3 replicates on different days.
  • NCCLS-M27-A Method for broth macro dilution antifungal susceptibility testing of yeasts; approved standard.
  • M38-P microdilution method for filmentous fungi also used.
  • CTAB cetyl trimethyl ammonium bromide
  • Compound (1) was tested against a range of clinical strains of Campylobacter spp. isolated from humans. TABLE 18 MIC/MMC ( ⁇ g/mL) of Compound (1) by NCCLS - M7 A5 macro dilution test, 42° C., 48 h, microaerophilic incubation MIC MMC Campylobacter jejuni 54/1-2 2 2 C. jejuni 541-3 2 2 C. coli 54/2 4 4 C. foetus 54/3 2 2 C. hyointestinalis 54/4 2 2 C. sputorium 54/5 2 2 C. laniolis 54/6 2 2 2
  • Campylobacter is the most common cause of gastroenteritis infection worldwide (bloody diarrhoea, abdominal pain, vomiting, headache, fever, lasting about 1 week). Sequelae are arthritis and Guillain-Barre syndrome(0.1%). It is acquired mainly from eating poultry. Incidence is about 2.5 million persons/year in USA. C. jejuni accounts for 99% of cases. It can vary from sub-clinical to severe in compromised patients. It is usually untreated with only fluid replacement or, if the disease is severe or threatening, with antibiotics (Erythromycin, tetracycline or fluoroquinolone).
  • N. gonorrhoeae is a cause of vaginitis in women.
  • Compound (1) is thus active at low concentrations against two causes, Candida albicans and N. gonorrhoeae.
  • the MIC of clinical isolate of Trichomonas vaginalis was determined by macrobroth dilution in Diamond's complete medium, modified by Klass (Modified TYM) as described by Garcia, L. Cultures were contained in 5 mL glass, screw-capped bottles without air-spaces. Volumes of 5 mL of log 2 dilutions, from 512 ⁇ g/mL Compound (1) in 5% DMSO to 0.25 ⁇ g/mL Compound (1) in 0.002% DMSO in modified TYM, were inoculated with 0.5 mL volume of cells in log phase of growth giving a final inoculum density of 1 ⁇ 10 4 to 3 ⁇ 10 4 cell/mL. Bottles were incubated aerobically at 37° C.
  • MIC was determined as the lowest concentration showing no motility. Aliquots of 0.5 mL from all tubes showing no motility were subcultured into further 5 mL volumes of modified TYM and incubated aerobically at 37° C. for up to 5 days to confirm non-viability.
  • Tests were validated by growth controls in TYM, modified TYM with 2.5% DMSO and modified TYM with 5% DMSO.
  • Fungi exhibit up to a four-fold difference in MIC on repeat testing. Significant increases in MIC are ⁇ 8-fold.
  • Compound (1) is very stable, dilute solutions retaining potency for 12 weeks on storage at 4° C. and ⁇ 20° C. Twofold loss of potency at room temperature after 6 weeks is very low compared to working solutions of antibiotics. It is also within the allowed variation range for MIC measurements for bacteria (2-fold). Control antifungals were not tested.
  • the aim of this example was to quantify the effect of Compound (1) on invasion and growth of the human malaria parasite Plasmodium falciparum in human red blood cells in vitro.
  • 3D7 is a well characterised in vitro culture-adapted line of P. falciparum that was used for these experiments.
  • the parasite undergoes repeating cycles of growth and replication within human red blood cells. The duration of each complete cycle is 48 hours, beginning with young ring-stage parasites which mature through pigmented trophozoites during the first 24 hours of the cycle to segmented schizonts which burst to release infectious merozoites which rapidly invade red blood cells. Newly invaded merozoites become ring forms, and the cycle continues.
  • P. falciparum parasites were maintained in synchronous in vitro culture in freshly collected human red blood cells, using well-established techniques. For invasion assays, red blood cells containing stage-synchronized mature, pigmented trophozoites were purified and resuspended in fresh human red blood cells, so that approximately two in every 100 red blood cells was parasitised (2% parasitaemia). Fresh culture media was added to give a final red blood cell concentration of 2 ⁇ 10 8 red cells/ml.
  • Compound (1) was tested as aqueous solutions of 100, 400 and 1000 ⁇ g/ml each containing 10% EtOH. Stock solutions were stored at 4° C. until required. For the assay, each solution was further diluted 1:40 in complete parasite culture medium (pH 7.2) to the desired working concentration (5, 10 and 25 ⁇ g/ml), then sterile filtered (0.22 ⁇ m) before being added to the parasitised red blood cell suspension. Stock solutions were stored at 4° C. throughout the duration of the assay, and diluted appropriately in parasite culture medium when required. It should be noted that at 1000 ⁇ g/ml, the compound was incompletely soluble, even after warming to 37° C. and vigorous vortexing. Thus the tests performed at a putative concentration of 25 ⁇ g/ml, may in fact have been performed at a lower effective concentration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/481,667 2001-06-18 2002-06-14 Antimicrobial and radioprotective compounds Abandoned US20040266844A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/923,404 US7825145B2 (en) 2001-06-18 2007-10-24 Antimicrobial and radioprotective compounds
US12/776,896 US8158664B2 (en) 2001-06-18 2010-05-10 Antimicrobial and radioprotective compounds
US13/425,054 US8569363B2 (en) 2001-06-18 2012-03-20 Antimicrobial and radioprotective compounds
US14/026,641 US9045452B2 (en) 2001-06-18 2013-09-13 Antimicrobial and radioprotective compounds
US14/728,854 US20150258059A1 (en) 2001-06-18 2015-06-02 Antimicrobial and radioprotective compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2001-117033 2001-06-18
RU2001117033/15A RU2259825C9 (ru) 2001-06-18 2001-06-18 Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
PCT/AU2002/000783 WO2002102789A1 (en) 2001-06-18 2002-06-14 Antimicrobial and radioprotective compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2002/000783 A-371-Of-International WO2002102789A1 (en) 2001-06-18 2002-06-14 Antimicrobial and radioprotective compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/923,404 Continuation US7825145B2 (en) 2001-06-18 2007-10-24 Antimicrobial and radioprotective compounds

Publications (1)

Publication Number Publication Date
US20040266844A1 true US20040266844A1 (en) 2004-12-30

Family

ID=20250935

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/481,667 Abandoned US20040266844A1 (en) 2001-06-18 2002-06-14 Antimicrobial and radioprotective compounds
US11/923,404 Expired - Fee Related US7825145B2 (en) 2001-06-18 2007-10-24 Antimicrobial and radioprotective compounds
US12/776,896 Expired - Fee Related US8158664B2 (en) 2001-06-18 2010-05-10 Antimicrobial and radioprotective compounds
US13/425,054 Expired - Fee Related US8569363B2 (en) 2001-06-18 2012-03-20 Antimicrobial and radioprotective compounds
US14/026,641 Expired - Fee Related US9045452B2 (en) 2001-06-18 2013-09-13 Antimicrobial and radioprotective compounds
US14/728,854 Abandoned US20150258059A1 (en) 2001-06-18 2015-06-02 Antimicrobial and radioprotective compounds

Family Applications After (5)

Application Number Title Priority Date Filing Date
US11/923,404 Expired - Fee Related US7825145B2 (en) 2001-06-18 2007-10-24 Antimicrobial and radioprotective compounds
US12/776,896 Expired - Fee Related US8158664B2 (en) 2001-06-18 2010-05-10 Antimicrobial and radioprotective compounds
US13/425,054 Expired - Fee Related US8569363B2 (en) 2001-06-18 2012-03-20 Antimicrobial and radioprotective compounds
US14/026,641 Expired - Fee Related US9045452B2 (en) 2001-06-18 2013-09-13 Antimicrobial and radioprotective compounds
US14/728,854 Abandoned US20150258059A1 (en) 2001-06-18 2015-06-02 Antimicrobial and radioprotective compounds

Country Status (10)

Country Link
US (6) US20040266844A1 (cg-RX-API-DMAC10.html)
EP (4) EP2471531B1 (cg-RX-API-DMAC10.html)
JP (3) JP5138146B2 (cg-RX-API-DMAC10.html)
CN (2) CN1863788B (cg-RX-API-DMAC10.html)
AU (1) AU2002311088B2 (cg-RX-API-DMAC10.html)
BR (1) BR0210506A (cg-RX-API-DMAC10.html)
CA (1) CA2450121C (cg-RX-API-DMAC10.html)
RU (1) RU2259825C9 (cg-RX-API-DMAC10.html)
WO (1) WO2002102789A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200309750B (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100258A1 (en) * 2003-02-28 2006-05-11 Ambrogina Nicoletti Growth promotion method
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2019023741A1 (en) * 2017-08-01 2019-02-07 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCUS AND ENTEROCOCCUS INFECTIONS USING SUBSTITUTED NITROSTYRENE COMPOUNDS
CN116836814A (zh) * 2023-06-28 2023-10-03 贵州省草业研究所 一株内生真菌及其在提高紫花苜蓿铝耐受性中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
CN102431408A (zh) * 2007-02-20 2012-05-02 田纳科汽车营运公司 用于精确的车辆高度的定位部件和方法
CN101077866B (zh) * 2007-05-15 2012-07-11 中国人民解放军第二军医大学 取代苯并噁唑类抗真菌化合物及其制备方法
AU2013204604B2 (en) * 2012-05-30 2016-05-19 Biodiem Limited Method of treating Scedosporium spp. infection
CN103910709A (zh) * 2014-03-05 2014-07-09 甘肃省农业科学院植物保护研究所 一种高活性化合物(e)-3-(3,4-亚甲基二氧基苯基)丙烯酸环己酰氨及其制备方法和应用
CN105875292A (zh) * 2016-04-12 2016-08-24 江苏大学 卵磷脂结合葡萄汁有孢汉逊酵母防治柑橘采后病害的方法
CN109400573B (zh) * 2017-08-17 2023-04-11 中国人民解放军第二军医大学 苯并[d][1,3]二氧杂环戊烯类化合物、制备方法及其应用
CN115025073B (zh) * 2022-06-23 2024-05-07 海南大学 一种苯烯烃硝基类化合物作为群体感应抑制剂的非经典抗菌活性用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469703A (en) * 1979-07-26 1984-09-04 Egyt Gyogyszervegyeszeti Gyar Nitroalkanol derivatives and plant protecting agents containing the same
US6329536B1 (en) * 1998-09-14 2001-12-11 Abbott Laboratories Stereoselective process for producing nitro compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE347818C (de) 1922-01-25 Adalbert Wagner Dr Verfahren zur Herstellung aromatischer ss-Nitropropenylverbindungen
US2233823A (en) * 1939-11-15 1941-03-04 Purdue Research Foundation Process for the reduction of arylnitroalkenes
US2762848A (en) * 1953-04-17 1956-09-11 Commercial Solvents Corp Process for chlorinating arylnitroalkenes
GB862175A (en) * 1956-09-28 1961-03-01 Ciba Ltd New benzimidazoles
FR2115089A1 (en) 1970-11-30 1972-07-07 Anvar Medicaments contg trans carbocyclic or heterocyclic - nitro ethylene cpds - as antitumour and cytoxic agents
DE2134419A1 (de) 1971-07-09 1973-01-25 Basf Ag Verfahren zur herstellung von 2-phenyl3-nitro-buttersaeure-verbindungen
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1210926B (it) * 1982-08-20 1989-09-29 Farmatis Srl Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.
JPS6242923A (ja) 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
ATE64854T1 (de) * 1986-05-22 1991-07-15 Atlantic Pharma Prod Zusammensetzung mit hemmender wirkung auf zumindest ein einzelliges lebewesen und/oder virus, herstellungsverfahren und anwendungen dieser zusammensetzung.
EP0447813A1 (en) * 1990-02-28 1991-09-25 GRUPPO LEPETIT S.p.A. Water soluble salts of purpuromycin and pharmaceutical formulations thereof
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
KR100460164B1 (ko) * 1995-12-04 2005-01-27 아벤티스 파마 도이칠란트 게엠베하 1-하이드록시-2-피리돈을포함하는난치성점막질환치료용약제학적조성물
PT888340E (pt) * 1996-02-13 2002-12-31 Abbott Lab Derivados de acido 4-(benzo-1,3-dioxolil)pirrolidino-3-carboxilico como antagonistas de endotelina
US5801250A (en) * 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
RU2145215C1 (ru) * 1997-04-18 2000-02-10 Денисенко Петр Прокофьевич Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
PL338678A1 (en) * 1997-08-22 2000-11-20 Merck & Co Inc Derivatives of 4-cyano-4-deformylsordacin
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
JPH11171773A (ja) * 1997-12-11 1999-06-29 Iyaku Bunshi Sekkei Kenkyusho:Kk ジヒドロ葉酸還元酵素の阻害剤
MA26628A1 (fr) * 1998-05-11 2004-12-20 Glaxo Wellcome Sa Morpholino ethers
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
RU2148215C1 (ru) 1998-12-21 2000-04-27 Конструкторское бюро "Арматура" Электродный нагреватель
CA2417500C (en) 2000-07-28 2008-11-18 Georgetown University Medical Center Erbb-2 selective small molecule kinase inhibitors
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469703A (en) * 1979-07-26 1984-09-04 Egyt Gyogyszervegyeszeti Gyar Nitroalkanol derivatives and plant protecting agents containing the same
US6329536B1 (en) * 1998-09-14 2001-12-11 Abbott Laboratories Stereoselective process for producing nitro compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100258A1 (en) * 2003-02-28 2006-05-11 Ambrogina Nicoletti Growth promotion method
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2019023741A1 (en) * 2017-08-01 2019-02-07 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCUS AND ENTEROCOCCUS INFECTIONS USING SUBSTITUTED NITROSTYRENE COMPOUNDS
CN116836814A (zh) * 2023-06-28 2023-10-03 贵州省草业研究所 一株内生真菌及其在提高紫花苜蓿铝耐受性中的应用

Also Published As

Publication number Publication date
JP5679128B2 (ja) 2015-03-04
WO2002102789A1 (en) 2002-12-27
JP5138146B2 (ja) 2013-02-06
JP5281960B2 (ja) 2013-09-04
HK1061856A1 (en) 2004-10-08
US9045452B2 (en) 2015-06-02
EP2468276B1 (en) 2015-11-11
EP1404665A4 (en) 2007-06-27
US8158664B2 (en) 2012-04-17
EP2468275A1 (en) 2012-06-27
BR0210506A (pt) 2004-05-18
EP2468275B1 (en) 2015-11-04
EP2468276A1 (en) 2012-06-27
JP2005511487A (ja) 2005-04-28
CN101804047A (zh) 2010-08-18
US8569363B2 (en) 2013-10-29
JP2013082719A (ja) 2013-05-09
CN1863788A (zh) 2006-11-15
EP1404665B1 (en) 2012-08-08
RU2259825C2 (ru) 2005-09-10
US20100292317A1 (en) 2010-11-18
CN101804047B (zh) 2012-12-26
ZA200309750B (en) 2005-05-25
CA2450121A1 (en) 2002-12-27
AU2002311088B2 (en) 2009-01-08
EP2471531A2 (en) 2012-07-04
US20140080876A1 (en) 2014-03-20
JP2009263372A (ja) 2009-11-12
EP2471531B1 (en) 2015-11-04
RU2259825C9 (ru) 2006-04-10
US20090012137A1 (en) 2009-01-08
CN1863788B (zh) 2010-05-12
US7825145B2 (en) 2010-11-02
CA2450121C (en) 2012-08-21
US20120225935A1 (en) 2012-09-06
US20150258059A1 (en) 2015-09-17
EP1404665A1 (en) 2004-04-07
EP2471531A3 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
US9045452B2 (en) Antimicrobial and radioprotective compounds
JP2009263372A6 (ja) 抗微生物及び放射線防御化合物
AU2002311088A1 (en) Antimicrobial and radioprotective compounds
US9867802B2 (en) Method of treating Scedosporium spp. infection
HK1172264A (en) Nitro-styrene derivatives having antimicrobial activity
HK1172263A (en) Nitrostyrenederivatives with antimicrobial action
HK1172262A (en) Nitrostyrene derivatives having antimicrobial action
HK1061856B (en) Antimicrobial compounds
HK1209052B (en) 3,4-methylenedioxy-beta-methyl-beta-nitrostyrene for use in the treatment of scedosporium spp. infection

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIODIEM LTD., AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENISENKO, PETER PROKOFIEVICH;SAPRONOV, KIKOLAY SERGEEVICH;TARASENKO, ALEXANDER ALEXANDROVICH;REEL/FRAME:015737/0722

Effective date: 20040227

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIODIEM LTD, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENISENKO, PETER PROKOFIEVICH;SAPRONOV, NIKOLAY SERGEEVICH;TARASENKO, ALEXANDER ALEXANDROVICH;REEL/FRAME:027896/0285

Effective date: 20040227

AS Assignment

Owner name: BIODIEM LTD, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENISENKO, PETER PROKOFIEVICH;SAPRONOV, NIKOLAY SERGEEVICH;TARASENKO, ALEXANDER ALEXANDROVICH;REEL/FRAME:035822/0460

Effective date: 20040227